title: Impact of adoption of a decision algorithm including PCA3 for repeat biopsy on the costs for prostate cancer diagnosis in France.
abstract: OBJECTIVE
  A recent expert study (RAND Appropriateness Method (RAM)) including a panel of 12 European urologists reported that the PCA3 score may be instrumental in taking appropriate prostate biopsy (PBx) decisions, mainly for repeat PBx. This study determined the cost/benefit balance of introducing PCA3 in the decision-making for PBx in France.
  
  
  METHODS
  Two RAM models, without and with PCA3, were retrospectively applied to a sample of 808 French men who had PBx in 2010 (78% first, 22% repeat). Outcome measures included the proportion of PBx that could have been avoided (i.e., judged inappropriate) in the French sample according to both RAM models, and the estimated impact of application of these models on the annual number of PBx and associated costs for France (based on most recent published data).
  
  
  RESULTS
  Complete profiles were available for 698 men. In the model without PCA3, 2% of PBx were deemed inappropriate. Knowledge of PCA3 would have avoided another 7% of PBx. Repeat PBx would have been avoided in 5% of cases without PCA3 and in 37% with PCA3. For France, application of the RAM model including PCA3 would result in 18,345 fewer repeat PBx. It would be budget-neutral in the unlikely hypothesis of no complications or no costs incurred by complications and would save €1.7 million for a mean cost for complications of €100/procedure or €5 million for a mean cost for complications of €280/procedure, calculated based on US and Canadian data.
  
  
  CONCLUSIONS
  Limitations of the study are the theoretical nature of the analysis and the fact that PCA3 distributions had to be derived from other sources.
  
  
  CONCLUSIONS
  Adoption of RAM expert recommendations including PCA3 for repeat PBx decisions in clinical practice in France would reduce the number of repeat PBx and control costs.
authors.affiliation: CHU de Toulouse, Hôpital de Rangueil, Toulouse, France. bernard.malavaud@numericable.fr
authors.forename: Bernard
authors.initials: B
authors.lastname: Malavaud
authors.forename: Olivier
authors.initials: O
authors.lastname: Cussenot
authors.forename: Nicolas
authors.initials: N
authors.lastname: Mottet
authors.forename: François
authors.initials: F
authors.lastname: Rozet
authors.forename: Alain
authors.initials: A
authors.lastname: Ruffion
authors.forename: Louis
authors.initials: L
authors.lastname: Smets
authors.forename: Herman
authors.initials: H
authors.lastname: Stoevelaar
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000951:Antigens, Neoplasm / Q000097:blood / Q000191:economics*; D001706:Biopsy / Q000191:economics* / Q000379:methods; D017046:Cost Savings; D003657:Decision Making; D005602:France; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000473:pathology; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology; D012189:Retrospective Studies
chemical_list: D000951:Antigens, Neoplasm; C479341:prostate cancer antigen 3, human